Skip to content

Observation on the Efficacy of High-Protein Nutritional Supplement Containing CaHMB in Elderly Patients with Osteoarthritis-Related Sarcopenia

Observation on the Efficacy of High-Protein Nutritional Supplement Containing CaHMB in Elderly Patients with Osteoarthritis-Related Sarcopenia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114126
Enrollment
Unknown
Registered
2025-12-08
Start date
2025-12-11
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Interventions

Intervention group:The intervention group was given CaHMB high-protein nutritional special powder, 15g daily, for 12 consecutive weeks.
Control group:The control group was given a high-protein nutritional special powder without CaHMB, 15g daily for 12 consecutive weeks.

Sponsors

Northern Jiangsu People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.age-related sarcopenia (fractures, degenerative osteoarthritis, osteoporosis, etc.); 2.age >=60 years, any gender or ethnicity; 3.meeting the Asian Working Group for Sarcopenia (AWGS) diagnostic criteria for sarcopenia, fulfilling the following conditions: (1)Reduced skeletal muscle mass, defined as BIA measurement with ASMI <7.0 kg/m² for men and <5.7 kg/m² for women, or DXA measurement with ASMI <7.0 kg/m² for men and <5.4 kg/m² for women; (2)Simultaneously meeting the criteria for decreased skeletal muscle strength, defined as handgrip strength <26 kg for men and <18 kg for women, or reduced physical performance, defined as gait speed <0.8 m/s; 4.able to tolerate enteral nutrition; 5.voluntarily agrees to and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Individuals who cannot tolerate enteral nutrition; 2.those with diseases that severely affect the digestion and absorption of the test product (such as short bowel syndrome or severe enteritis); 3.patients with severe cardiac, hepatic, or renal dysfunction, serious neuropsychiatric disorders, or tumors who are undergoing radiotherapy or chemotherapy, as well as patients with edema; 4.those currently using other nutritional preparations that may affect the study outcomes; 5.patients using medications that may influence the study results (such as hormones, antitumor drugs, sedatives, or other muscle relaxants); 6.individuals whom the investigator deems unsuitable for participation in this study; 7.and those who have not signed the informed consent form.

Design outcomes

Primary

MeasureTime frame
Indices of skeletal muscles in limbs, ASMI;Advantageous grip strength;6-Meter Walking Speed Test;Complete Blood Count;

Secondary

MeasureTime frame
Serum albumin;Body Mass Index, BMI;Upper arm circumference;Calf circumference;

Countries

China

Contacts

Public ContactYu Sun

Northern Jiangsu People's Hospital2025

docsy@163.com+86 180 5106 0619

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026